InvestSMART

Dorsavi Ltd (ASX:DVL)

ALERT: Price-sensitive ASX Announcement for DVL
Current share price for DVL : $0.026 -0.012 (-31.58%)+
Announcement
Release
29 Jan 2026 8:58AM
Price at Release
$0.038
Full Release
download
Summary
dorsaVi Ltd reported a significant strategic and operational progress for the quarter ending December 31, 2025. The company successfully expanded its commercial operations in the US Physical Therapy market, signing over 100 new sites, largely driven by a partnership with Select Medical. Financials showed an increase in customer cash receipts to $280,000 from $185,000 in the previous quarter, supported by the US franchise deal. The company also reported a cash balance of $4.95 million at the quarter's end. Key strategic initiatives included a leadership transition with Mathew Regan taking over as CEO, a notable technological acquisition enhancing their robotics and edge platform capabilities, and an advanced silicon roadmap aiming at RRAM integration. These actions position dorsaVi as a leader in next-generation edge AI and robotics intelligence platforms.
Key Points
  • Accelerated US Commercial Growth with over 100 new Physical Therapy sites signed.
  • Cash receipts from customers increased to $280k.
  • Leadership transition with Mathew Regan as CEO.
  • Acquisition of exclusive Neuromorphic Process-In-Memory IP.
  • Initiated 22nm RRAM integration for high bit density and lower energy consumption.
  • Cash balance of $4.95 million as of 31 December 2025.
  • Successful execution of a five-year sales agreement with Select Medical.
  • Focus on high-value AI, RRAM, and robotics.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.